APM
LKFT

Avidity Partners Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Avidity Partners Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-215,000
Closed -$13.3M – 89
2022
Q1 		$13.3M Buy
+215,000
New +$13.2M 0.28% 59

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Avidity Partners Management's LKFT Position: Q2 2022 in Review

Avidity Partners Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2022, closing a stake of 215,000 shares — an estimated $13.3M sold.

Avidity Partners Management first reported a position in LKFT in Q1 2022 and held it in 1 quarter. The position peaked at $13.3M in Q1 2022. 82 funds tracked by Wall St. Rank hold LKFT as of Q2 2022.

  • Avidity Partners Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2022 after selling out during the quarter.
  • Avidity Partners Management sold 215,000 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2022, an estimated $13.3M.
  • Avidity Partners Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2022 and held it in 1 quarter.
  • Avidity Partners Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $13.3M in Q1 2022.
  • 82 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.